Related coverage linked through entity extraction aliases.
Aug 08, 2026
CAR-T therapy reaches 150 patients in Ireland and expands into autoimmune trials for lupus and MS. Kyverna's miv-cel nears FDA approval for stiff person syndrome, and new research links gene variants to CAR-T outcomes.
Jul 10, 2026
Phase I CARLYSLE trial data show CAR-T therapy obe-cel induces remission in severe refractory lupus with a favorable safety profile. Separate case report documents two successful pregnancies after dual-target CAR-T therapy with no transmission to infants.
Jul 01, 2026
Two new studies advance Lyme disease research: anti-lipid antibodies may enable earlier diagnosis and detect persistent symptoms, while cell wall changes in Borrelia burgdorferi offer insights into Lyme arthritis pathogenesis and potential treatment targets.
Apr 21, 2026
Eli Lilly and Company has agreed to acquire Orna Therapeutics for up to $2.4 billion in cash. The deal includes ORN-252, a clinical-trial-ready CD19-targeting in vivo CAR-T therapy for B cell-driven autoimmune diseases.
Apr 07, 2026
GLP-1 drugs discovered accidentally in anglerfish research now treat conditions beyond diabetes including kidney disease, sleep apnea, and addiction. The global diabetes therapeutics market is projected to reach $241.5 billion by 2030, growing at 12.4% annually.
Feb 26, 2026
Eli Lilly announced the acquisition of Orna Therapeutics for up to $2.4 billion on February 9, 2026, gaining access to proprietary circular RNA technology and an "in vivo" CAR-T platform for immunology and oncology applications.
Feb 14, 2026
Researchers have developed modified CAR T cells that overcome prostaglandin E2 suppression in solid tumors and a selective therapy targeting IGHV4-34 that spares healthy immune cells, addressing key limitations in current treatments.
Dec 18, 2025
SCOPE 2026 in Orlando recognized innovation in clinical research with three awards programs, honoring Biogen's lupus webinar series, TrialScreen's site connection initiative, and Biorce's AI platform among 70 competing products.
